Publication not explained

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.

Featured Image

Read the Original

This page is a summary of: The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and luticasone propionate via Accuhaler® (ENERGITO® study), International Journal of Chronic Obstructive Pulmonary Disease, February 2016, Dove Medical Press,
DOI: 10.2147/copd.s95055.
You can read the full text:

Read
Open access logo

Contributors

The following have contributed to this page